Azithromycin is an azalide antibiotic, and its mechanism of action is to bind to the 50s ribosomal subunit of sensitive microorganisms, thereby interfering with their protein synthesis (without affecting nucleic acid synthesis). It is effective against a variety of pathogens, including Gram-positive aerobic microorganisms, some Gram-negative aerobic microorganisms, and Mycoplasma trachomatis.

It interferes with protein synthesis (without affecting nucleic acid synthesis) by binding to the 50s ribosomal subunit of sensitive microorganisms. It is effective against Staphylococcus aureus, Streptococcus pyogenes, Streptococcus pneumoniae, hemolytic Streptococcus, Haemophilus influenzae, Moraxella catarrhalis, Mycoplasma trachomatis, etc. It can prevent diseases caused by avian intracellular mycobacterium complex. It has cross-resistance to erythromycin-resistant Gram-positive bacteria and is ineffective against strains producing beta-lactamase.

This product is an amide local anesthetic. After blood absorption or intravenous administration, it has obvious biphasic effects of excitation and inhibition on the central nervous system, and there may be no precursor excitation. When the blood concentration is low, analgesia and drowsiness occur, and the pain threshold increases; with increasing doses, the effect or toxicity increases, and it has an anticonvulsant effect at sub-toxic blood concentrations; convulsions may occur when the blood concentration exceeds 5μg·ml-1. At low doses, this product can promote the outflow of K in myocardial cells, reduce myocardial autonomy, and have an anti-ventricular arrhythmia effect; at therapeutic doses, it has no obvious effect on the electrical activity of myocardial cells, atrioventricular conduction, and myocardial contraction; further increases in blood concentrations can cause a slowing of heart conduction velocity, atrioventricular conduction block, inhibition of myocardial contractility, and a decrease in cardiac output.

It participates in amino acid metabolism, synthesis of neurotransmitters, synthesis of collagen and tissue cell interstitial, can reduce the permeability of capillaries, accelerate blood coagulation, stimulate coagulation function, promote iron absorption in the intestine, promote the decrease of blood lipids, increase resistance to infection, participate in detoxification function, and has antihistamine effect and prevents the formation of carcinogens (nitrosamines).

Tranexamic acid competitively inhibits the adsorption of plasminogen to the fibrin network, reducing plasminogen activation and thus preventing fibrin degradation and bleeding.